NIKKEI 225
38,079.70 +117.90 (+0.31%) HANG SENG
16,439.41 +187.57 (+1.15%) CRUDE OIL
82.72 +0.03 (+0.04%) GOLD FUTURES
2,393.60 +5.20 (+0.22%) DOW
37,753.31 -45.66 (-0.12%) Bitcoin GBP
48,848.21 -2,374.21 (-4.64%)
Pharming Group N.V. (0QCO.L)
| Previous close | 0.7790 |
| Open | 0.8000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.8000 - 0.8095 |
| 52-week range | 0.8000 - 0.8095 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 5.038M |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 0.54 |
| EPS (TTM) | 0.0150 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswirePharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group N.V. launches new convertible bond offering and simultaneously invites holders of its outstanding €125 million 3.00% convertible bonds due 2025 to offer their convertible bonds for purchase for cash Leiden, the Netherlands, 18th April, 2024: Pharming Group N.V. ("Pharming" or the "Company"
GlobeNewswirePharming announces completion of enrollment in pediatric clinical trial of leniolisib
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces the completion of patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged
- GlobeNewswire
Pharming Group announces the 2024 Annual General Meeting of Shareholders
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”) will be held on Tuesday, May 21, 2024 at 14:30 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The agenda of the AGM includes the reappointment of Ms. Barbara Y
